PMID: 9526055Apr 4, 1998Paper

Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis-and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug treatment

Brain Research. Molecular Brain Research
A C ChenH M Gurling

Abstract

It has been hypothesized that glutamate receptor function is important in both the aetiology and treatment of schizophrenia. In order to understand how specific glutamate receptor genes are involved in the treatment of schizophrenia we have used a multiprobe oligonucleotide solution hybridization (MOSH) technique to examine the regulation of gene express of the NMDAR1, 2A, 2B, 2C, 2D receptor subunits in the left rat brain following treatment with the optical isomers of flupenthixol. cis- and trans-flupenthixol are both present in the commonly used oral and depot treatments for schizophrenia and a controlled trial showed that cis-flupenthixol had a significantly superior ability to ameliorate the positive symptoms of schizophrenia compared to its trans-isomer. At a dose of 0.2 mg/kg/day over a period of 1, 2, 4, 8, 12 and 24 weeks, we found that both isomers down regulated the expression of NMDAR1 mRNA in most regions of the brain. NMDAR2A, 2B and 2C receptor subunits showed a significantly decreased expression from 12 to 24 weeks but after 2 weeks NMDAR2B, 2C, 2D expression was increased in several brain regions. The NMDAR1 receptor subunit immunoreactivity in the right brain following 4 and 24 weeks of drug treatment was also...Continue Reading

References

Sep 1, 1978·The American Journal of Psychiatry·R M Allen, S J Young
May 1, 1991·Brain Research. Molecular Brain Research·A De La ConchaH M Gurling
Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Jan 1, 1991·Schizophrenia Bulletin·H Y Meltzer
Nov 7, 1991·Nature·K MoriyoshiS Nakanishi
Jun 1, 1989·Journal of Neurochemistry·J F DeakinA J Cross
Dec 1, 1995·Archives of General Psychiatry·J W Olney, N B Farber
Feb 1, 1996·The American Journal of Psychiatry·S E Hyman, E J Nestler
Mar 1, 1996·Psychopharmacology·B J Kinon, J A Lieberman
Jan 1, 1996·Harvard Review of Psychiatry·J T Coyle
Aug 1, 1965·The British Journal of Psychiatry : the Journal of Mental Science·D S BELL
Jul 1, 1962·The American Journal of Psychiatry·E D LUBYE F DOMINO

❮ Previous
Next ❯

Citations

Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Peter M ThompsonMarquis P Vawter
Mar 27, 2009·Neurochemical Research·María Geraldina Bersier, Georgina Rodríguez de Lores Arnaiz
Jan 12, 2007·Journal of Cognitive Neuroscience·Jürgen GallinatGeorg Winterer
Sep 11, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tohru Ohnuma, Heii Arai
May 13, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Josette S Lindahl, Joyce Keifer
Apr 24, 2001·Molecular Psychiatry·T OhtsukiT Arinami
Jun 2, 2005·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·S J López-PérezC Beas-Zárate

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here